Tsvetelina Pencheva Hoang

Tsvetelina Pencheva Hoang currently serves as Chief Scientific Officer at Virovek, Inc., a position held since August 2024. Previously, Tsvetelina worked at Marker Therapeutics, Inc. as Vice President of Research and Development from October 2018 to August 2024, and held the same title at TapImmune Inc. for a brief period in 2018. Tsvetelina also served as Director of Translational Research and Senior Scientist at Bellicum Pharmaceuticals, Inc. from February 2015 to July 2018, and worked as an Instructor at MD Anderson Cancer Center from January 2013 to January 2015. Tsvetelina's early career includes a role as a Research Associate at Memorial Sloan-Kettering Cancer Center and HHMI research associate at UC-Berkeley. Tsvetelina earned a PhD in Biology from The Johns Hopkins University and a BS/MS in Molecular Biophysics and Biochemistry from Yale University.